Antagomir Technology in the Treatment of Different Types of Cancer

References

• Paccez JD , DuncanK , SekarDet al. Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl. Oncogenesis8(3), 14 (2019).
   PubMedGoogle Scholar
• Bray F , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• Sekar D , ShilpaBR , DasAJ. Relevance of microRNA 21 in different types of hypertension. Curr. Hypertens. Rep.19(7), 57 (2017).
   PubMed Web of Science ®Google Scholar
• Li Z , RanaT. Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov.13(8), 622–638 (2014).
   PubMed Web of Science ®Google Scholar
• Zaimy MA , SaffarzadehN , MohammadiAet al. New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther.24(6), 233–243 (2017).
   PubMed Web of Science ®Google Scholar
• Mohr AM , MottJL. Overview of microRNA biology. Semin. Liver Dis.35(1), 3–11 (2015).
   PubMed Web of Science ®Google Scholar
• Yue J . miRNA and vascular cell movement. Adv. Drug Deliv. Rev.63(8), 616–622 (2011).
   PubMed Web of Science ®Google Scholar
• Krutzfeldt J , RajewskyN , BraichRet al. Silencing of microRNAs in vivo with antagomirs. Nature438(7068), 685–689 (2005).
   PubMed Web of Science ®Google Scholar
• Cheng CJ , BahalR , BabarIAet al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature518(7537), 107–110 (2015).
   PubMed Web of Science ®Google Scholar
• Chang C . Approaches to autoimmune diseases using epigenetic therapy. Epigenet. Hum. Dis.2, 25–251 (2012).
   Google Scholar
• Atri C , GuerfaliFZ , LaouiniD. MicroRNAs in diagnosis and therapeutics. AGO-Driven Non-coding RNAs6, 137–177 (2019).
   Google Scholar
• Chen Q , ChenJ , WangCet al. MicroRNA-466o-3p mediates β-catenin-induced podocyte injury by targeting Wilms tumor 1. FASEB J.34(11), 14424–14439 (2020).
   PubMed Web of Science ®Google Scholar
• Wang W , WangM , XuJet al. Overexpressed GATA3 enhances the sensitivity of colorectal cancer cells to oxaliplatin through regulating MiR-29b. Cancer Cell Int.20, 339 (2020).
   PubMed Web of Science ®Google Scholar
• Yu J , ChenS , NiuYet al. Functional significance and therapeutic potential of miRNA-20b-5p in esophageal squamous cell carcinoma. Mol. Ther. Nucleic Acids21, 315–331 (2020).
   PubMedGoogle Scholar
• Zhu Y , LiK , YanLet al. miR-223-3p promotes cell proliferation and invasion by targeting Arid1a in gastric cancer. Acta Biochim. Biophys. Sin. (Shanghai)52(2), 150–159 (2020).
   PubMed Web of Science ®Google Scholar
• Song J , LiuY , WangTet al. MiR-17-5p promotes cellular proliferation and invasiveness by targeting RUNX3 in gastric cancer. Biomed. Pharmacother.128, 110246 (2020).
   PubMed Web of Science ®Google Scholar
• Geng Y , ZhaoS , JiaYet al. miR-95 promotes osteosarcoma growth by targeting SCNN1A. Oncology Rep.43(5), 1429–1436 (2020).
   PubMed Web of Science ®Google Scholar
• Zheng WP , MengFL , WangLY. miR-544a stimulates endometrial carcinoma growth via targeted inhibition of reversion-inducing cysteine-rich protein with Kazal motifs. Mol. Cell. Probes53, 101572 (2020).
   PubMed Web of Science ®Google Scholar
• Wang H , WangF , OuyangWet al. MALAT1 knockdown inhibits hypopharyngeal squamous cell carcinoma malignancy by targeting microRNA-194. Oncology Lett.20(1), 173–182 (2020).
   PubMed Web of Science ®Google Scholar
• Ling H , GeorgeAC. The role of microRNAs and ultraconserved non-coding RNAs in cancer. Cancer Genomics25, 435–447 (2014).
   Google Scholar
• Song MS , RossiJJ. The anti-miR21 antagomir, a therapeutic tool for colorectal cancer, has a potential synergistic effect by perturbing an angiogenesis-associated miR30. Front. Genet.4, 301 (2014).
   PubMed Web of Science ®Google Scholar
• Berindan-Neagoe I , MonroigP del C , PasculliBet al. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J. Clin.64(5), 311–336 (2014).
   PubMed Web of Science ®Google Scholar
• Liu A , ZhuJ , WuGet al. Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma. Mol. Cancer16(1), 106 (2017).
   PubMedGoogle Scholar
• Su J , WuF , XiaHet al. Accurate cancer cell identification and microRNA silencing induced therapy using tailored DNA tetrahedron nanostructure. Chem. Sci.11(1), 80–86 (2020).
   PubMed Web of Science ®Google Scholar
• Cheng C , BahalR , BabarIet al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature518(7537), 107–110 (2015).
   PubMed Web of Science ®Google Scholar
• Li Z , RanaTM. Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov.13(8), 622–638 (2014).
   PubMed Web of Science ®Google Scholar
• Gao Y , PatilS , QianA. The role of microRNAs in bone metabolism and disease. Int. J. Mol. Sci.21(17), 6081 (2020).
   PubMed Web of Science ®Google Scholar
• Diekwisch T . Novel approaches toward managing the micromanagers: ‘non-toxic’ but effective. Gene Ther.23(10), 697–698 (2016).
   PubMed Web of Science ®Google Scholar
• Ling H , FabbriM , CalinG. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov.12(11), 847–865 (2013).
   PubMed Web of Science ®Google Scholar
• Tivnan A , OrrWS , GubalaVet al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE7(5), e38129 (2012).
   PubMed Web of Science ®Google Scholar